AR and benign prostatic hyperplasia: Therefore, androgens and androgen receptor (AR)-mediated signaling may contribute to an increase in the prostatic volume, and 5α-reductase inhibitors that suppress testosterone conversion into DHT and decrease the DHT-induced expression of prostate-specific antigen (PSA) are effective medicines for reducing prostate enlargement in patients with BPH.